ライフサイエンスコーパス: unrelated donor

1 56) with recurrent disease after alloSCT (11 unrelated donors).

2 e with sibling donors and 64% for those with unrelated donors).

3 indicated but who lack a matched related or unrelated donor.

4 ed donor, either a sibling (>40-50 years) or unrelated donor.

5 from an HLA-identical sibling and 40 from an unrelated donor.

6 loablative allogeneic procedure involving an unrelated donor.

7 transplantation urgently or lack a 7-8 of 8 unrelated donor.

8 able to rapidly identify a suitably matched unrelated donor.

9 sibling, 884 from a 7 or 8 of 8 HLA-matched unrelated donor.

10 y human leukocyte antigen-matched related or unrelated donor.

11 rgoing HCT from a matched-related or matched-unrelated donor.

12 tical sibling or a partially or well-matched unrelated donor.

13 ceipt of a transplant from an HLA-mismatched unrelated donor.

14 re haemopoietic cell transplantation from an unrelated donor.

15 nor, and many patients do not have a matched unrelated donor.

16 underwent HCT from 9/10 or 10/10 HLA-matched unrelated donors.

17 FMT using frozen encapsulated inoculum from unrelated donors.

18 M were serious comorbidities and grafts from unrelated donors.

19 is comparable to that of matched related or unrelated donors.

20 ls (PBPCs) from 8 of 8 or 7 of 8 HLA-matched unrelated donors.

21 equent depression diagnosis among nonspousal unrelated donors.

22 aged 40 to 49 years; older cohorts had more unrelated donors.

23 em-cell and bone marrow transplantation from unrelated donors.

24 not correlate significantly with outcomes in unrelated donors.

25 y-two patients had related donors and 34 had unrelated donors.

26 first from HLA-identical siblings and later unrelated donors.

27 and 52% of patients received stem cells from unrelated donors.

28 atched related donors and 39 had HLA-matched unrelated donors.

29 SCT using human leukocyte antigen-mismatched unrelated donors.

30 or umbilical cord blood (14%); 53% were from unrelated donors.

31 gs (n=5), and matched (9) and mismatched (2) unrelated donors.

32 results of transplantation from HLA-matched unrelated donors.

33 atopoietic-cell transplants from related and unrelated donors.

34 ients of hematopoietic-cell transplants from unrelated donors.

35 , and 38% of patients had matched/mismatched unrelated donors.

36 of hematopoietic-cell transplants and their unrelated donors.

37 (1.5%) mismatch related, and 4 (6%) mismatch unrelated donors.

38 human leucocyte antigen-matched related and unrelated donors.

39 haemopoietic cell transplantation when using unrelated donors.

40 HLA match are important when selecting adult unrelated donors.

41 ed donors, and 31 (72%) received grafts from unrelated donors.

42 ized blood cells from HLA-matched related or unrelated donors.

43 followed by HCT from HLA-matched related or unrelated donors.

44 e HLA locus received bone marrow grafts from unrelated donors.

45 rom HLA-matched, and 41% from HLA-mismatched unrelated donors.

46 HLA-identical siblings or HLA allele-matched unrelated donors.

47 tic-cell transplants from matched related or unrelated donors.

48 d-blood donor (140 patients), an HLA-matched unrelated donor (344), or an HLA-mismatched unrelated do

49 m HLA-matched siblings (40%) or well-matched unrelated donors (48%).

50 th related donors (79% vs 39%; P = .001) and unrelated donors (53% vs 26%; P < .001).

51 nts, 7 received HSCT from related and 4 from unrelated donors; 9 patients received busulfan-based con

52 unrelated donor (344), or an HLA-mismatched unrelated donor (98).

53 utcomes in 390 US patients and their matched unrelated donors, accrued between 1995 and 2004.

54 ived HCT from an HLA-identical sibling or an unrelated donor after intravenous busulfan plus cyclopho

55 Allogeneic HCT from related or unrelated donors after conditioning with low-dose TBI an

56 transplantation of umbilical-cord blood from unrelated donors after myeloablative chemotherapy.

57 We examined current outcomes of unrelated donor allogeneic hematopoietic cell transplant

58 l grafts were associated with survival after unrelated-donor allogeneic hematopoietic stem-cell trans

59 patients received bone marrow grafts from an unrelated donor and a myeloablative conditioning regimen

60 receipt of a transplant from an HLA-matched unrelated donor and was significantly higher than the pr

61 rtunities for LDKTx, centers may accept more unrelated donors and adopt programs to overcome biologic

62 acilitated by the increasing availability of unrelated donors and cord blood, and the inclusion of ol

63 fter transplantation of cord blood (CB) from unrelated donors and evaluated strategies for screening

64 e Bu-Flu patients were older, more often had unrelated donors and had a shorter follow-up.

65 ematopoietic cell transplantation (HCT) from unrelated donors and in the setting of solid organ trans

66 ajority (52%) received transplantations from unrelated donors and were given antithymocyte globulin f

67 We obtained blood from healthy unrelated donors and, using a panel of 45 alpha3(IV)NC1

68 or mismatched family donor, 3.97% in matched unrelated donors, and 11.24% in mismatched unrelated don

69 elated donors, 2 received PBSCs from matched-unrelated donors, and 2 received stem cells from umbilic

70 and more comorbidities, more frequently had unrelated donors, and more often had malignancy in remis

71 nonmyeloablative transplant strategies using unrelated donors are expanding rapidly, but relapse rate

72 ematopoietic cell transplantation (HCT) from unrelated donors as compared with related donors.

73 transplantation of umbilical-cord blood from unrelated donors before the development of symptoms woul

74 Conclusions and Relevance: Recipients of unrelated donor BM had better psychological well-being,

75 partially matched sibling BM or PB (n = 24), unrelated donor BM or PB (n = 313), single (n = 89) or d

76 Interventions: Unrelated donor BM or PB hematopoietic cell transplantat

77 od stem cells (PBSCs), and 675 recipients of unrelated donor BM transplants.

78 Potential benefits of unrelated donor BMT for FA, however, have been severely

79 se (GVHD), and mortality in 98 recipients of unrelated donor BMT who received transplants between 199

80 Outcome after unrelated donor bone marrow (BM) transplantation for sev

81 n a multicenter randomized clinical trial of unrelated donor bone marrow (BM) vs peripheral blood (PB

82 gnostic factors that influence outcome after unrelated donor bone marrow transplantation in children

83 -host disease (GVHD) reduces the efficacy of unrelated donor bone marrow transplantation in patients

84 pse are long-term survivors, suggesting that unrelated donor bone marrow transplantation is an effect

85 ection are important obstacles to successful unrelated donor bone marrow transplantation, irrespectiv

86 were 6%, 15%, and 31% after matched sibling, unrelated donor bone marrow, and cord blood HCT, respect

87 etic cell transplantation and, compared with unrelated donor bone marrow, has the advantages of rapid

88 er haemopoietic cell transplantation from an unrelated donor, but evidence of patient benefit is abse

89 ffect were age >/= 50 years, female sex, and unrelated donor, but not the intensity of the conditioni

90 For patients lacking a matched family donor, unrelated donors can be readily found, although mostly f

91 Transplantation of hematopoietic cells from unrelated donors can cure blood disorders but carries a

92 eneic HSCT from both HLA-matched sibling and unrelated donors can induce durable clinical, molecular,

93 therapy followed by allo-SCT from related or unrelated donors can provide durable remission even in e

94 (P = .03), but not for recipients of younger unrelated donor CD8(lo) grafts (P = .28).

95 relapsing CDI using a frozen suspension from unrelated donors, comparing colonoscopic and nasogastric

96 Use of unrelated donor cord blood (CB) as an alternative stem c

97 Unrelated donor cord blood transplantation from partiall

98 Outcomes of unrelated donor cord blood transplantation in 191 hemato

99 rgoing LDKTx at centers with greater use of "unrelated donors" (defined as nonspouses and nonfirst-de

100 Using PBSCs from unrelated donors does not appear to be more beneficial t

101 leukocyte antigen-matched sibling or from an unrelated donor during the years 2000 to 2006 for acute

102 to 40 years and 165% [corrected] increase in unrelated donors for alloHCT, overall survival (OS) at d

103 n of hematopoietic stem cells (HSCs) from an unrelated donor, frequently residing in another country,

104 In this study of 936 patients who had unrelated donors, genotypes of single nucleotide polymor

105 erval from diagnosis to transplantation, and unrelated donor grafts adversely affected OS in multivar

106 gnificantly better for recipients of younger unrelated donor grafts with CD8(hi) doses (P = .03), but

107 2 and 10% of patients receiving related and unrelated donor grafts.

108 Seronegative patients receiving seropositive unrelated-donor grafts had decreased overall survival (h

109 to 55%) and 50% (95% CI, 38% to 64%) for the unrelated donor group.

110 tween the cord-blood group and the two other unrelated-donor groups appeared to vary according to the

111 disease was significantly higher in the two unrelated-donor groups than in the cord-blood group (haz

112 patients receiving grafts from seropositive unrelated donors had improved overall survival (HR, 0.92

113 Patients with HLA-matched related or unrelated donors had similar survivals.

114 alternative donors such as mismatched adult unrelated donors, haploidentical related donors, and umb

115 Umbilical cord blood transplantation from unrelated donors has been previously shown to improve ne

116 older patients and the more frequent use of unrelated donors has led to increased numbers of patient

117 mobilized peripheral blood from related and unrelated donors has yet to be established.

118 analyzed data from 2062 patients undergoing unrelated donor HCT for acute myeloid leukemia (AML; n =

119 oning regimens before a related or volunteer-unrelated donor HCT for refractory acute myeloid leukaem

120 Though leukemia recurrence was lowest after unrelated donor HCT in first clinical remission (CR), ov

121 of pretransplantation DSAs in recipients of unrelated donor HCT is associated with failed engraftmen

122 Unrelated donor HCT recipients were younger, more likely

123 Unrelated donor HCT should be considered for infants wit

124 A, -B, -C, and -DRB1 is required for optimal unrelated donor HCT survival, and avoidance of nonpermis

125 rates were similar after matched sibling and unrelated donor HCT, after adjustment for disease status

126 were tested to evaluate the role of DSAs in unrelated donor HCT.

127 tal body irradiation followed by HLA-matched unrelated-donor HCT and postgrafting cyclosporine and MM

128 s much as 80% of all patients who receive an unrelated donor hematopoietic cell transplant (HCT) for

129 itive), we studied PBMCs obtained 6 mo after unrelated donor hematopoietic cell transplantation (HCT)

130 These interactions affect the outcome of unrelated donor hematopoietic cell transplantation (HCT)

131 inform donor selection to improve outcome of unrelated donor hematopoietic cell transplantation for a

132 very likely to be broadened as results after unrelated donor hematopoietic cell transplantation impro

133 atening risks associated with HLA-mismatched unrelated donor hematopoietic cell transplantation limit

134 ated SNPs and adverse outcomes after matched unrelated donor hematopoietic cell transplantations in U

135 M) loci on the outcome of 2687 myeloablative unrelated donor hematopoietic cell transplantations perf

136 pid adoption of treatment strategies such as unrelated donor hematopoietic stem cell transplant and t

137 nd 299 patients in CR2 in undergoing matched unrelated donor hematopoietic stem cell transplantation

138 TRM) and should be avoided to secure optimal unrelated donor hematopoietic stem cell transplantations

139 reactivation on T-cell reconstitution after unrelated-donor hematopoietic stem cell transplant.

140 or chimerism, all 3 recipients of mismatched unrelated donor HSCT had high levels of donor T-cell chi

141 Unrelated donor HSCT recipients were at greatest risk.

142 Matched unrelated donor HSCT should be considered for all patien

143 identical sibling or a 10/10 allelic-matched unrelated donor in the same period.

144 fferences in the HLA alleles of patients and unrelated donors in hematopoietic stem cell transplantat

145 Transplantation of umbilical-cord blood from unrelated donors in newborns with infantile Krabbe's dis

146 se (GVHD) limits the use of HLA-C-mismatched unrelated donors in transplantation.

147 We aim to use matched related and unrelated donors (including cord blood) whenever possibl

148 ore resources, more transplant teams, and an unrelated donor infrastructure.

149 HLA-C, HLA-DRB1, and HLA-DQB1 allele-matched unrelated donor is a well-recognized life-saving treatme

150 or sources when a matched related or matched unrelated donor is not available.

151 marrow, especially when an HLA-matched adult unrelated donor is not available.

152 ct on overall survival if a CMV-seropositive unrelated donor is selected for a CMV-seronegative patie

153 lity study, FMT using a frozen inoculum from unrelated donors is effective in treating relapsing CDI.

154 In conclusion, PBSC collection in unrelated donors is generally safe, but nearly all donor

155 D), but the safety and efficacy of HSCT from unrelated donors is less certain.

156 Several case studies suggest that unrelated-donor leukocyte infusion effectively induces d

157 m cell transplantation has led to the use of unrelated-donor leukocyte infusion in many patients.

158 There is a paucity of data on unrelated-donor leukocyte infusion in this setting.

159 But the role for unrelated-donor leukocyte infusion is not well establish

160 review summarizes recent data on the use of unrelated-donor leukocyte infusion.

161 Living-unrelated donors (LURD) have been shown to yield kidney

162 The optimum preparative regimen for unrelated donor marrow transplantation in patients with

163 in a randomized multicenter trial involving unrelated donor marrow transplants.

164 (CY, 50 mg/kg x 4) to achieve engraftment of unrelated donor marrow.

165 ng either BM (n = 225) or PBPC (n = 71) from unrelated donors matched at human leukocyte antigen-A, -

166 ved hematopoietic stem-cell transplants from unrelated donors matched for HLA-A, B, C, DR, and DQ or

167 rtance: Bone marrow or peripheral blood from unrelated donors may be used for hematopoietic cell tran

168 ntical (haplo)-related donor, and mismatched unrelated donor (MMUD) are available.

169 ot available, a haploidentical or mismatched unrelated donor (mMUD) can be useful.

170 HLA-mismatched unrelated donor (MMUD) hematopoietic stem-cell transplan

171 g HSCT from an MRD (n = 4) or an HLA-matched unrelated donor (MUD) (n = 7); 9 children were boys, and

172 Ph)-positive patients were offered a matched unrelated donor (MUD) allogeneic SCT.

173 s younger than 40-50 years, with HLA-matched unrelated donor (MUD) HSCT for second line after failure

174 For the remaining patients, a matched unrelated donor (MUD) is an alternative.

175 with a younger allele-level 8/8 HLA-matched unrelated donor (MUD) rather than an older HLA-matched s

176 ing alloHSCT with a sibling (sib) or matched unrelated donor (MUD) to patients younger than 55 years

177 the development of graft failure in matched unrelated donor (MUD) transplantation remains unclear.

178 o hundred patients were grafted from matched unrelated donor (MUD), of these, 129 (64.5%) received an

179 -matched sibling donor (SIB) and HLA-matched unrelated donor (MUD).

180 a male human leukocyte antigen (HLA)-matched unrelated donor (MUD, 8/8, n=2,014) might be an alternat

181 ted donor (MRD, n = 204), HLA allele-matched unrelated donor (MUD, n = 152) or 1-antigen-mismatched u

182 a matched related (MRD, n = 29) or a matched unrelated donor (MUD, n = 3), 20 to autoHSCT in CR1 and

183 HLA) matched related donor (MRD) and matched unrelated donors (MUD) produces similar survival for pat

184 atched sibling donors (MRDs) and HLA-matched unrelated donors (MUDs).

185 haploidentical (n = 192) and 8/8 HLA-matched unrelated donor (n = 1982) transplantation.

186 cell transplantation from related (n = 9) or unrelated donors (n = 15) in 15 institutions worldwide w

187 were matched unrelated donors or mismatched unrelated donors (n = 18) and matched related donors (n

188 hematopoietic cells from related (n = 45) or unrelated donors (n = 2).

189 ed transplantations from sibling (n = 11) or unrelated donors (n = 23) between 2003 and 2009.

190 ) as a preparative regimen and patients with unrelated donors (n = 34) receiving conditioning with Fl

191 atched unrelated donors (n = 72), mismatched unrelated donors (n = 37), matched sibling donors (n = 1

192 tained from HLA-matched siblings (n = 4) and unrelated donors (n = 4).

193 Donors were matched unrelated donors (n = 72), mismatched unrelated donors (

194 tween 1990 and 2009 from related (n = 86) or unrelated donors (n = 84).

195 Among recipients of transplantations from unrelated donors, no significant differences in event-fr

196 gher degrees of donor T-cell chimerism after unrelated donor nonmyeloablative HCT and suggest that ta

197 eles in patients and their 10/10 HLA-matched unrelated donors of 379 HCTs performed at our center for

198 leukocyte antigen-identical sibling or match unrelated donor options.

199 ation of reconstituting NK cells after adult unrelated donor or umbilical cord blood grafting.

200 Stem cell donors were matched unrelated donors or mismatched unrelated donors (n = 18)

201 LDTR quartiles were also more likely to use "unrelated" donors (OR 8.30 per tertile of higher use; P<

202 3; 95% CI, 1.13 to 1.79; P = .01), use of an unrelated donor (P = .03), and RIC (HR, 0.79; 95% CI, 0.

203 o had related donors vs 34.1% for those with unrelated donors, p=0.0206).

204 We report outcomes of 932 recipients of unrelated donor peripheral blood stem cell hematopoietic

205 replaced bone marrow (BM) as the most common unrelated donor progenitor cell product collected, a dir

206 This article reviews aspects of the Living Unrelated Donor program and development of deceased dona

207 Recipients of matched-related and -unrelated donors received fludarabine and 200 cGy of tot

208 extensively human leukocyte antigen-matched, unrelated donor-recipient pairs by using multivariate Co

209 association with the risk of chronic GVHD in unrelated donor-recipient pairs from 1 cohort, but none

210 e associations was replicated when tested in unrelated donor-recipient pairs from an independent coho

211 in related donor-recipient pairs but not in unrelated donor-recipient pairs.

212 In addition to mismatch at minor H loci, unrelated donor/recipient pairs exhibit genetic disparit

213 Although the 8 matched related or unrelated donor recipients had full donor chimerism, all

214 Matched unrelated donor recipients showed a 3.8-fold elevated ri

215 d unrelated donors, and 11.24% in mismatched unrelated donor recipients.

216 5%) living-related versus none of the living-unrelated donors' recipients recurred.

217 Use of unrelated donors, reduced-intensity conditioning and the

218 The development of unrelated donor registries and increased utilization of

219 Unrelated donor registries contributed 22.3 million type

220 eukocyte antigen (HLA)-matched family donor, unrelated donor registries of adult volunteers and banke

221 ithout a suitable related HLA-matched donor, unrelated-donor registries of adult volunteers and banke

222 lodysplastic syndrome, and their HLA-matched unrelated donors, reported to the Center for Internation

223 ts, allogeneic HSCT from matched related and unrelated donors resulted in a limited improvement of ov

224 and provides guidance and regulations about unrelated donor safety and care.

225 Prospective typing of patients and donors in unrelated donor search may identify mismatches for MICA-

226 typing of several best HLA-matched potential unrelated donors should substantially increase the frequ

227 trials and a recently completed trial using unrelated donor stem cells has been reported.

228 gation in both ablative and nonmyeloablative unrelated-donor stem cell transplantation.

229 on the use of donor leukocyte infusion after unrelated-donor stem cell transplantation.

230 ral-blood stem cells versus bone marrow from unrelated donors to compare 2-year survival probabilitie

231 s) in 2628 patients and their HLA-mismatched unrelated donors to determine whether SNPs are associate

232 conditioning followed by a matched 10 of 10 unrelated donor transplant from BM or peripheral blood s

233 Matched unrelated donor transplant recipients received CNI with

234 e-matched (at HLA-A, -B, -C, and -DRB1 loci) unrelated donor transplant.

235 of human leukocyte antigen (HLA) matching in unrelated donor transplantation for nonmalignant disease

236 ociated with significant organ toxicity) for unrelated donor transplantation for severe aplastic anae

237 tive conditioning and few early deaths after unrelated donor transplantation for severe aplastic anae

238 re 49% and 54% after HLA-matched sibling and unrelated donor transplantation in first CR, respectivel

239 te that BM is the preferred graft source for unrelated donor transplantation in SAA.

240 Outcome after HLA-mismatched unrelated donor transplantation is influenced by MHC reg

241 The immunogenicity of HLA-C mismatches in unrelated donor transplantation is influenced by the exp

242 Among unrelated donor transplantation recipients, the RRs for

243 Optimizing the results of unrelated donor transplantation requires an understandin

244 A total of 236 recipients of unrelated donor transplantation were studied.

245 te lymphoblastic leukemia who are undergoing unrelated donor transplantation with myeloablative total

246 in 87 transplant pairs that received matched unrelated donor transplantation, especially for RFS (P=0

247 otal body irradiation-based conditioning and unrelated donor transplantation, in the present study, w

248 relatively higher risk: patients undergoing unrelated donor transplantation, receiving TBI, and thos

249 used and produces similar results to matched unrelated donor transplantation.

250 settings, when used in matched, related, and unrelated donor transplantation.

251 y are matched has not been fully defined for unrelated donor transplantation.

252 randomized to receive 1 of 2 graft types for unrelated donor transplantation.

253 cyclophosphamide is comparable with matched unrelated donor transplantation.

254 elated, HLA-matched unrelated, or mismatched unrelated donor transplantation.

255 registered adult donors, and the numbers of unrelated donor transplantations are increasing.

256 s 15% at 4 years (8% for sibling and 22% for unrelated donor transplantations), acute grade 2 or 3 gr

257 r after haploidentical compared with matched unrelated donor transplants (90% vs 97%, P = .02).

258 CI, 47-53) after haploidentical and matched unrelated donor transplants (P = .38).

259 associated with deleterious effects in 3853 unrelated donor transplants stratified according to numb

260 oes not significant affect these outcomes in unrelated donor transplants suggesting that the strength

261 811 HLA-matched sibling (61%) and 522 (39%) unrelated donor transplants.

262 onic GVHD was only observed in recipients of unrelated donor transplants.

263 r after haploidentical compared with matched unrelated donor transplants.

264 HLA-matched related-donor and 35 HLA-matched unrelated-donor transplants were done.

265 Studies in unrelated donor (UD) hematopoietic stem cell transplanta

266 similar at 81%, 66% after 10/10 HLA-matched unrelated donor (UD), and 68% after 5/6 matched CB donor

267 rom matched sibling donors (MSD; n = 21) and unrelated donors (UD; n = 29), using fludarabine 30 mg/m

268 etic cell transplantation (HCT), sibling and unrelated donors (UDs) are biologically different becaus

269 oietic stem cell transplantation (HSCT) with unrelated donors (UDs) showed no association between the

270 A 12-month-old boy underwent unrelated donor umbilical cord blood transplant (UCBT) f

271 myelomonocytic leukemia, given single-unit, unrelated donor umbilical cord blood transplantation.

272 ransplantation with partially HLA-mismatched unrelated donor umbilical cord blood were studied to inv

273 hed related-donor transplantation (MMRDT) or unrelated-donor umbilical cord blood transplantation (UC

274 For patients lacking a suitable family or unrelated donor, umbilical cord blood provides a promisi

275 nt-related mortality (TRM) and relapse after unrelated donor (URD) hematopoietic cell transplantation

276 antation of hematopoietic stem cells from an unrelated donor (URD) is an option for many patients who

277 ived haploidentical (n = 185) or HLA-matched unrelated donor (URD) transplantation either with (n = 2

278 is review summarizes the state of the art of unrelated donor (URD) umbilical cord blood transplantati

279 al risk that use myeloablative conditioning, unrelated donor (URD), and methotrexate are not known.

280 syndrome, transplanted from related donors, unrelated donors (URD), or unrelated cord blood between

281 chemotherapy-based conditioning from matched unrelated donors (URDs), either from volunteer adults or

282 with unfavorable cytogenetics using matched unrelated donors (URDs).

283 -identical sibling donors (SDs; n = 3191) or unrelated donors (URDs; n = 2370) and reported to the Ce

284 GVHD was more common in matched unrelated donor vs matched sibling donor recipients and

285 ifference in eGFR slopes between related and unrelated donors was 0.20 mL/min/1.753 m(2) /year (0.07-

286 ions of transplants from matched siblings or unrelated donors were 54% and 46%.

287 ecent years, and from HLA-matched related or unrelated donors were associated with a significantly be

288 ior relapse resistant to therapy, and use of unrelated donors were associated with higher NRM.

289 lthy first-degree relatives, and 141 healthy unrelated donors were measured for IFNalpha activity usi

290 Nine unrelated donors were mismatched for >/= one HLA antigen

291 rd blood transplants and marrow from matched unrelated donors were similar (31%, 95% CI 27-35 and 32%

292 ated-donors or HLA-9/10 or HLA-10/10 matched unrelated-donors were infused.

293 a, and 10 Diamond-Blackfan anemia) and their unrelated donors who had pre-HCT blood samples and clini

294 eral-blood mononuclear cells from related or unrelated donors who received granulocyte colony-stimula

295 A-genoidentical siblings or from HLA-matched unrelated donors who were identified and matched by high

296 A search for an unrelated donor will be undertaken for patients without

297 Whether the same benefits accrue from unrelated donors will require further follow-up.

298 is an effective therapy, whereas AHSCT from unrelated donors with FluMel/ATG conditioning led to a h

299 This analysis demonstrates that unrelated donors with KIR B haplotypes confer significan

300 transplants from HLA-A,B,C,DRB1,DQB1-matched unrelated donors with only one HLA-DPB1 mismatch, linkag